The Weekly Summary

WICHITA, KS - MARCH 5:  Republican presidential candidate Ted Cruz makes a speech at a campaign rally on March 5, 2016 in Wichita, Kansas. Cruz said he has a list of government programs that he will eliminate if elected. (Photo by J Pat Carter/Getty Images)

February 29th – March 6th                                

 In the general news, Trump won most of the Super Tuesday states, while Ted Cruz looks to become the solid alternative Trump, winning states on Saturday. Bernie Sanders also stayed relevant by winning Kansas and Nebraska on Saturday. Elsewhere, the economy added 242,000 jobs in February.

In healthcare business news, Valeant (VRX) continues to make news, adding an SEC investigation to its woes, and the CEO returned from medical leave.

On the data front, Vitae (VTAE) shares plunged after a psoriasis trial of VTP-43742 was unable to fully enroll. Baxalta (BXLT) backed out a deal with Onconova (ONTX) for cancer drug rigosertib.

From the FDA, privately held American company CSL Behring won approval for hemophilia B drug Idelvion.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.